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Abstract
Background: The "real" effect size of a medical therapy is constant over time. In contrast, the
effect size reported in randomised controlled trials (RCTs) may change over time because the sum
of all kinds of bias influencing the reported effectiveness is not necessarily constant. As this would
affect the validity of meta-analyses, we tested the hypothesis that the reported effect size decreases
over time. Furthermore, we tested three hypotheses that would explain a possible change.
Methods: Because of well established outcome measures, the lipid-lowering drugs Pravastatin and
Atorvastatin (serum low-density lipoprotein cholesterol, LDL-C) and the anti-glaucoma drugs
Timolol and Latanoprost (intraocular pressure, IOP) were chosen for this investigation. Studies
were identified by a standardized MEDLINE search. RCTs investigating the above identified
medications administered as monotherapy, and in defined dosages, were included. Publication year,
baseline (= pre-treatment value in the treatment group of interest) and post intervention means,
number of patients and the assignment to experimental or control group were extracted for each
study.
Results: A total of 625 citations were screened; 206 met the inclusion criteria. The reported effect
size of Pravastatin (change of reported effect size in five years: -3.22% LDL-C, P < .0001), Timolol
(-0.56 mmHg, P < .0001) and Latanoprost (-1.78 mmHg, P = .0074) decreased over time, while
there was no significant change for Atorvastatin (+0.31% LDL-C, P = .8618). Multiple regression
analysis showed that baseline values were the most important influencing factor; study size or
treatment group did not play a significant role.
Conclusion: The effectiveness of medical therapies reported in RCTs decreases over time in
three of the four investigated pharmaceuticals, caused mainly by baseline differences. We call this
phenomenon "fading of reported effectiveness". Under this condition the validity of a meta-analysis
may be impaired. Therefore we propose to observe this phenomenon in future meta-analyses in
order to guarantee a maximum of transparency.
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Background
Recently, meta-analyses have become an instrument that
is fundamental to the idea of best medical care. Meta-anal-
yses combine the results of a high number of randomised
controlled trials (RCTs) to a special topic in order to gain
more significant results. Should the reported effect size of
RCTs change with time, the result of a meta-analysis
would depend on when it was performed. Thus, the valid-
ity of a meta-analysis could be impaired.
Nevertheless, an extensive literature search on this topic
yielded no results in the medical field, but we identified
one relevant study in biology. Jennions and Møller
recently examined 44 meta-analyses covering topics like
animal behaviour, parasitism and plant growth [1]. They
found a small, but highly significant, decline in the
strength of reported correlations with publication date
(best model: P < .0001; R = -0.133) and with sample size
(best model: P < 0.002; R = -0.188). In other words, the
investigated meta-analyses would estimate higher inter-
vention effects if they had been performed earlier. The
authors attributed the decrease to Publication Bias
(under-reporting of studies with small sample sizes and
little effect) and Time of Publication Bias (studies that
report large effect sizes are published sooner than other
studies). Unfortunately, they did not investigate if sample
size increased with publication year and they did not
describe the time lag between study completion and pub-
lication date for the individual studies which would have
been necessary to verifying their hypotheses. Moreover, as
it remains unclear whether results from the field of biol-
ogy apply as well to medical research, this paper reports a
meta-analysis of clinical drug trials to examine the
reported effectiveness of medical treatments over time.
The objective of our longitudinal meta-analysis was to
determine if the effect size of medical therapies, as
reported in RCTs, changes with time. Further we aimed to
identify reasons for any possible change. The unit of anal-
ysis was the individual study and not the individual trial
participant.
But why should the effect size of a medical intervention
change with time? Our hypothesis is based on the
assumption that we have to distinguish between the "real"
effectiveness of a medical therapy and the effectiveness
reported in RCTs, and that the latter may change with
time.
(1) The true biological effect size of a medical therapy is
constant over time, meaning it should be possible to
obtain similar results when a trial is repeated at a later date
under identical conditions.
(2) The sum of all kinds of bias influencing the reported
effect size of a medical therapy is not necessarily constant
over time. In the course of time social, political and eco-
nomic circumstances for medical research and its publica-
tion change. Therefore, it can be assumed that the impact
of the various potential sources of bias changes with time
in a highly dynamic way. In consequence, the effect size of
a medical therapy, as reported in RCTs, may change over
time.
As we presumed that, if there was any change at all, the
reported effectiveness of medical therapies was more
likely to decrease than to increase, we tested three hypoth-
eses that might explain a decrease in the reported effect
size:
(a) Decreasing Publication Bias
The problem of Publication Bias is well known in the
medical literature [2-5]. Studies with positive outcomes
and significant results are more likely to get published,
leading to an under-representation of studies with nega-
tive or non-significant results in meta-analyses. Since the
level of significance rises with increasing study size, the
problem of Publication Bias more likely applies to studies
with smaller sample sizes. New medical therapies are first
tried in small selected populations, followed by bigger tri-
als, with the aim of validating the benefits in larger popu-
lations. Increasing study size should lead to a decrease in
Publication Bias, and to lower reported effect sizes over
time.
(b) Spectrum bias (a particular form of selection bias)
New medical interventions tend to be studied in severely
ill patients where significant benefits can be expected.
After a therapy is established, physicians tend to broaden
its use and prescribe it to a wide range of patients, includ-
ing a high number of less sick patients. In addition, spe-
cific treatment goals have been developed in recent years
for several diseases such as hypertension, diabetes melli-
tus and glaucoma; patients who might not have been
treated a decade ago, today receive therapy. In less sick
patients, less improvement of the study parameter can be
expected. Over time the effectiveness of the therapy seems
to diminish.
(c) "Shift of treatment group" bias
Although the studies were conducted as RCTs, expecta-
tions of patients, physicians and study authors may play a
role, favouring the therapy used in the experimental treat-
ment group. Over time, medical therapies originally con-
sidered as innovative therapies become established, and,
in later studies, are no longer innovative and therefore
implemented as control therapies. This may lead to a
decrease in the reported effect size over time.BMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
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To answer our questions we examined data from a large
number of RCTs dealing with the effectiveness of four dif-
ferent pharmaceuticals. The primary outcome measure
was the reported effect size; secondary outcome measures
were the publication year, the study size, the mean pre-
intervention level of the investigated parameter and the
treatment assignment to experimental or control group.
Methods
Selection of pharmaceuticals
The pharmaceuticals to be investigated in this experiment
had to comply with the following requirements: (1) Their
effectiveness was measurable in terms of commonly
accepted quantitative parameters that are reported in most
studies; (2) the pharmaceuticals were administered as a
monotherapy, and in a fixed dosage in order to obtain a
high number of studies with comparable results; (3) the
therapies were of clinical importance and of general inter-
est. For our investigation, we arbitrarily chose the lipid-
Flow diagram Figure 1
Flow diagram. Abbreviations: RCT, randomized controlled trial; n, number of trials. * Parameter of interest: Reported effec-
tiveness of the pharmaceutical, measured as change of intraocular pressure (Timolol, Latanoprost) or change in low-density 
lipoprotein cholesterol (Pravastatin, Atorvastatin). ** Dose of interest: In terms of comparability studies that did not use the 
pharmaceutical in the most common dosage were excluded, as well as studies that increased the individual dosage until a cer-
tain outcome was reached.
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lowering drugs Pravastatin and Atorvastatin (route of
administration: oral; outcome measure: change of serum
low-density lipoprotein cholesterol) and the anti-glau-
coma drugs Timolol and Latanoprost (eye drops; change
of intraocular pressure).
Data sources
A standardized literature search was performed with
emphasis on transparency and repeatability rather than
on completeness. Our MEDLINE search strategy included
the following text strings [6]: "Pravastatin LDL", "Atorvas-
tatin LDL", "Timolol glaucoma", and "Latanoprost glau-
coma". The literature search was performed for the time
up to and including December 2001. The MEDLINE
search was limited to studies on human subjects and to
items with abstracts only. A filter for randomised control-
led trials was used. Non-English studies were included.
Study selection
A study was included if it met the following criteria: (1)
baseline value and post-intervention value of the parame-
ter of interest were reported, i. e. low-density lipoprotein
cholesterol for Pravastatin and Atorvastatin, intraocular
pressure for Timolol and Latanoprost; (2) the pharmaceu-
tical was administered as monotherapy and after a wash-
out period; (3) the pharmaceutical was administered in
the most commonly used dosage, i. e. Pravastatin 40 mg
once daily, Atorvastatin 10 mg once daily, Timolol 0.5 %
twice daily, and Latanoprost 0.005 % once daily; (4) the
study was conducted as a randomised controlled trial.
One investigator (BTG) reviewed 625 citations and
selected appropriate studies. 274 studies were considered
for more detailed evaluation. Eventually, 206 studies were
deemed appropriate for inclusion (Figure 1).
Data extraction
One of the authors (BTG) extracted the following data for
each study: publication year, study size (number of evalu-
ated patients), pre- and post-intervention mean values of
low-density lipoprotein cholesterol/intraocular pressure
(baseline = pre-treatment value in the treatment group of
interest), and assignment to experimental or control
group.
Where necessary, means were approximated from figures
in the manuscripts or calculated from individual patient
data. In each study, the effect size for the intervention was
calculated by the difference between the means of the
treatment group of interest before and after intervention.
In some studies, more than one post-intervention mean
was reported; e. g., for different follow-up visits or for dif-
ferent hours of the day. In these cases, the arithmetic
mean of the given means was calculated instead of choos-
ing one of the given means arbitrarily. Unfortunately,
standard deviations of effect sizes could not generally be
reported as they were not included in all original papers.
For the same reason it was not possible to perform a
weighted analysis.
A study was given the designation "control group", if the
pharmaceutical of interest was compared with at least one
newer pharmaceutical. The designation "experimental
group" was chosen if the pharmaceutical of interest was
compared with older pharmaceuticals, or if no other phar-
maceuticals were involved in the study (e. g. placebo-con-
trolled studies or studies comparing the effectiveness of
different dosages of the same pharmaceutical).
We realized that it was difficult to find independent stud-
ies published over a period of 10 years which investigated
exactly the same treatment in "exactly" the same patients.
Unfortunately, it was not possible to find studies that used
– in addition to the above criteria – the same comparative
treatments. We found many consecutive studies but the
comparative treatments used in these studies varied from
trial to trial. As a consequence the other treatments that
varied from study to study were not included in our anal-
ysis.
Statistical analysis
Statistical analysis was performed with SAS software (SAS
release 8.02, SAS Institute Incorporated, Cary, USA). For
each of the variables (publication year, reported effect
size, baseline and study size) arithmetic means and stand-
ard deviations were calculated. The reported effect size
was measured in the most commonly reported dimension
(Pravastatin and Atorvastatin: change of low-density lipo-
protein cholesterol in percentages; Timolol and Latano-
prost: change of intraocular pressure in mmHg). As the
variable treatment group is dichotomous with the two
possibilities experimental and control group, exact fre-
quencies are reported. In addition, we calculated the arith-
metic mean of the publication year of those studies coded
as "control" versus those coded as "experimental".
We examined the association between year and effect size
and the association between year and other study charac-
teristics. The primary outcome variable (reported effect
size) and the secondary outcome variables (baseline,
study size and treatment group) were regressed against the
publication year. For the variable treatment group, point
biserial correlation was used (control group = 0, experi-
mental group = 1). For every correlation the equation of
the regression line and the limits of its 95 percent confi-
dence intervals (CI) were calculated (a positive correlation
would mean increasing effect sizes with time, a negative
correlation decreasing effect sizes with time). With that,
the mean change of every variable during an interval of
five years (± 95 % CI) was calculated (a positive sign onBMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
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the mean change would mean an increase, a negative sign
a decrease with time).
Pearson correlation coefficients and P-values were calcu-
lated for all variables that may influence the effect size. We
used a standard approach for statistical significance (α =
0.05). The funnel plot technique was used to detect pub-
lication bias [7-9]: Diagrams of the relation between study
size and reported effect size were drawn and visually
checked for asymmetry.
Furthermore we quantified the impact of the different var-
iables on the reported effect size. For this, we performed a
multiple regression analysis with reported effect size as
the outcome variable and publication year, baseline,
study size, and treatment group as possible predictors. Up
to two predictors were entered into the model.
We investigated if measuring the primary outcome varia-
ble in absolute or relative dimensions changes the signifi-
cance levels of the results. Bivariate qualitative analysis
and multiple regression analysis were performed with
reported effect size measured in absolute terms (Pravasta-
tin and Atorvastatin: low-density lipoprotein cholesterol
change in mg/dl, Timolol and Latanoprost: intraocular
pressure change in mmHg) and in relative terms (change
of outcome variable in percentages).
We could not investigate the change of reported effective-
ness in the control therapies of the pharmaceutical of
interest, because the control therapies were different in
almost any of the studies. The chance to find a study com-
paring exactly the same control and experimental group
several years later is rather low.
Results
Included trials and trial characteristics
A total of 206 studies were included in the final analysis
(Figure 1). 64 of the included studies investigate Pravasta-
tin, 35 Atorvastatin, 75 Timolol, and 32 Latanoprost. For
a list of the individual trials [see Additional file 1], for the
extracted raw data [see Additional file 2].
Table 1 shows the mean (± standard deviation, SD) year
of publication, reported effect size, baseline value, and
study size for each of the four investigated medical thera-
pies. For the dichotomous variable treatment group
(experimental/control group) exact frequencies are given,
and in addition the mean year of publication in depend-
ence of the treatment group. Pravastatin lowered the low-
density lipoprotein cholesterol (LDL-C) on average by
29.50 percent (± 4.16), Atorvastatin by 36.07 percent (±
3.70); Timolol lowered the intraocular pressure (IOP) on
average by 6.55 mmHg (± 1.56), Latanoprost by 6.83
mmHg (± 1.53).
Table 1: Trial characteristics
Pravastatin (n = 64) Atorvastatin (n = 35)
Mean ± SD Min. Max. Mean ± SD Min. Max.
Year of publication 1995.28 ± 3.46 1990 2001 1999.40 ± 1.82 1996 2001
Reported effect size* -29.50 ± 4.16 -19.0 -39.0 -36.07 ± 3.70 -28.4 -44.2
Baseline† 205.62 ± 47.78 134.4 344.0 198.05 ± 35.05 143.0 340.3
Study size‡ 595.77 ± 1511.59 10 9014 328.71 ± 686.64 22 3916
Treatment group§ EG: 56 (87%); CG: 8 (13%) EG: 31 (89%); CG: 4 (11%)
Timolol (n = 75) Latanoprost (n = 32)
Mean ± SD Min. Max. Mean ± SD Min. Max.
Year of publication 1992.68 ± 6.99 1978 2001 1999.06 ± 2.00 1995 2001
Reported effect size -6.55 ± 1.56 -3.65 -11.3 -6.83 ± 1.53 -3.5 -9.8
Baseline 25.94 ± 2.49 20.8 38.7 24.07 ± 2.13 19.3 28.2
Study size 197.96 ± 249.59 12 1198 152.81 ± 195.57 20 829
Treatment group EG: 12 (16%); CG: 63 (84%) EG: 29 (91%); CG: 3 (9%)
Abbreviations: n, number of trials that met selection criteria; SD, standard deviation; EG, experimental group; CG, control group.
* Unit of measurement for reported effect size: Change of intraocular pressure measured in mmHg (Timolol, Latanoprost), change in low-density 
lipoprotein cholesterol measured in % (Pravastatin, Atorvastatin).
† Unit of measurement for baseline: Intraocular pressure measured in mmHg (Timolol, Latanoprost), low-density lipoprotein cholesterol measured 
in mg/dl (Pravastatin, Atorvastatin). To convert low-density lipoprotein cholesterol from milligrams per deciliter to millimoles per liter, multiply 
milligrams per deciliter by 0.0259.
‡ Unit of measurement for study size: Number of patients included in final analysis.
§ As the variable "treatment group" is either "experimental group" or "control group", exact frequencies and percentages are given.BMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
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Effect of time on investigated variables
Over time, the reported effect size decreased significantly
for three of the four investigated pharmaceuticals (Figure
2; Table 2 and 3). Pravastatin on average was reported to
lower the patient's LDL-cholesterol by 3.22 percent less
every five years (95% confidence interval: ± 1.28; P <
0.0001), meaning e. g. by 29.74 percent in 1995 and by
26.52 percent in 2000. Timolol was reported to reduce the
intraocular pressure by 0.56 mmHg less every five years (±
0.22; P < 0.0001), Latanoprost by 1.78 mmHg less every
five years (± 1.26; P = 0.0074). For Atorvastatin, the
reported effect size did not change significantly over time
(P = 0.8618).
Most of the other investigated variables changed over time
as well (Table 2 and 3). The baseline values of the variable
of interest decreased over time for all investigated phar-
maceuticals. This relation was significant for Pravastatin (-
41.80 mg/dl LDL-C every five years; P < 0.0001) and
Timolol (-0.70 mmHg IOP every five years; P = 0.0004).
Study size increased over time for three of the four phar-
maceuticals; this relation was significant only for Timolol
(+80.55 patients every five years; P < 0.0001). The variable
treatment group changed over time from experimental
group towards control group for all investigated pharma-
ceuticals. This relation was significant for Pravastatin (-
0.20 every five years, meaning that in all Pravastatin stud-
ies, every five years 20 percent less used Pravastatin in the
experimental treatment arm and 20 percent more in the
control arm; P = .0008) and for Timolol (-0.12 every five
years ; P < .0001).
Other bivariate analyses
For Pravastatin, Timolol and Latanoprost the reported
effect size correlated significantly with the baseline values
of the variable of interest (Table 3). The reported effect
Regression analysis of the relation between year of publication and reported effectiveness of Pravastatin (y = 90.818 – 0.643x;  P < 0.0001), Atorvastatin (y = 29.900 + 0.062x; P = 0.8618, not significant), Timolol (y = 16.983 – 0.113x; P < 0.0001), and  Latanoprost (y = 42.069 – 0.356x; P = 0.0074) Figure 2
Regression analysis of the relation between year of publication and reported effectiveness of Pravastatin (y = 90.818 – 0.643x; 
P < 0.0001), Atorvastatin (y = 29.900 + 0.062x; P = 0.8618, not significant), Timolol (y = 16.983 – 0.113x; P < 0.0001), and 
Latanoprost (y = 42.069 – 0.356x; P = 0.0074). Abbreviations: IOP, intraocular pressure; LDL-C, low-density lipoprotein cho-
lesterol; x, reported effectiveness (for Timolol and Latanoprost change of IOP measured in mmHg, for Pravastatin and Atorv-
astatin change of LDL-C measured in %); y, year of publication minus 1900.
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size was related to treatment group for Atorvastatin (P =
0.0092). There was no significant correlation between
study size and reported effect size (in the most commonly
reported dimension) for any of the investigated pharma-
ceuticals.
Measuring effect size in relative or absolute dimensions
Some results of the lipid lowering drugs were altered
when the reported effect size was measured in absolute
and not in relative terms. When measuring the change of
LDL-C in mg/dl and not in percentages, (1) the relation
between reported effect size and baseline value was signif-
icant for Atorvastatin (P < .0001 vs. P = 0.4045), (2)the
relation between reported effect size and treatment group
Table 3: Bivariate qualitative analyses of all investigated parameters. Significant correlations (P < 0.05) are highlighted by bold digits
Reported effect size* Baseline Study size Treatment group†
Ph R‡ P-value Ph R P-value Ph R P-value Ph R P-value
Year of Publication P: -0.5360 <.0001 P: -0.6056 <.0001 P: 0.2444 0.0517 P: -0.4092 0.0008
A: 0.0305 0.8618 A: -0.1518 0.3840 A: 0.1237 0.4789 A: -0.3207 0.0603
T: -0.5043 <.0001 T: -0.3955 0.0004 T: 0.4512 <.0001 T: -0.4513 <.0001
L: -0.4642 0.0074 L: -0.3413 0.0559 L: -0.0346 0.8508 L: -0.3167 0.0774
Reported effect size 1.00 P: 0.2591 0.0387 P: -0.1899 0.1327 P: 0.1598 0.2073
A: -0.1454 0.4045 A: 0.0381 0.8281 A: -0.4339 0.0092
T: 0.6949 <.0001 T: -0.1364 0.2432 T: 0.1565 0.1801
L: 0.8745 <.0001 L: 0.2206 0.2251 L: 0.0289 0.8753
Baseline 1.00 P: -0.2897 0.0202 P: 0.0872 0.4933
A: -0.0868 0.6201 A: 0.0848 0.6282
T: -0.1923 0.0983 T: 0.0686 0.5587
L: 0.2673 0.1392 L: -0.1069 0.5604
Study size 1.00 P: 0.0566 0.6568
A: 0.1106 0.5269
T: -0.2723 0.0181
L: -0.3557 0.0457
Abbreviations: Ph, pharmaceutical; T, Timolol; L, Latanoprost; P, Pravastatin; A, Atorvastatin.
* Reported effect size for Pravastatin and Atorvastatin is measured in relative terms (%), for Timolol and Latanoprost in absolute terms (mmHg).
† As the parameter treatment group only has the possibilities control group (= 0) or experimental group (= 1), point biserial correlation was used.
‡ R: Pearson correlation coefficient.
Table 2: Bivariate quantitative analyses of all investigated parameters in dependence of year of publication. All given data are 
calculated from the equations of the regression lines. For P-values see table 3
Pravastatin Atorvastatin Timolol Latanoprost
Reported effect size* Change in 5 years -3.22 +0.31 -0.56 -1.78
95% CI limits (-4.50/-1.93) (-3.29/+3.91) (-0.79/-0.34) (-3.04/-0.51)
Baseline† Change in 5 years -41.80 -14.63 -0.70 -1.82
95% CI limits (-55.74/-27.86) (-48.38/+19.11) (-1.08/-0.32) (-3.69/+0.05)
Study size‡ Change in 5 years +533.54 +233.63 +80.55 -16.94
95% CI limits (-3.94/+1071.01) (-429.97/+897.23) (+43.38/+117.71) (-199.23/+165.35)
Treatment group§ Change in 5 years -0.20 -0.28 -0.12 -0.23
95% CI limits (-0.31/-0.08) (-0.58/+0.01) (-0.17/-0.06) (-0.50/+0.03)
Abbreviations: CI, confidence interval; LDL-C, low-density lipoprotein cholesterol.
* Unit of measurement for reported effect size: Change of intraocular pressure measured in mmHg (Timolol, Latanoprost), change in low-density 
lipoprotein cholesterol measured in % (Pravastatin, Atorvastatin).
† Unit of measurement for baseline: Intraocular pressure measured in mmHg (Timolol, Latanoprost), low-density lipoprotein cholesterol measured 
in mg/dl (Pravastatin, Atorvastatin). To convert low-density lipoprotein cholesterol from milligrams per deciliter to millimoles per liter, multiply 
milligrams per deciliter by 0.0259.
‡ Unit of measurement for study size: Number of patients included in final analysis.
§ The parameter treatment group has two possibilities: control group = 0, experimental group = 1. Point biserial correlation was used to obtain the 
equation of the regression line and to calculate the given data.BMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
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was not any more significant for Atorvastatin (P = 0.3731
vs. P = 0.0092), and (3) the relation between reported
effect size and study size was significant for Pravastatin (P
= 0.0139 vs. P = 0.1327). For Timolol and Latanoprost the
results were not altered if the reported effect size was
measured in relative terms and not in absolute terms.
Multiple regression analysis
The results of the multiple regression analysis differed if
the effect size was measured in absolute or in relative
terms. If measured in absolute terms the baseline was the
most reliable predictor and alone explained 80.37 percent
of the variability of the reported effect size of Pravastatin
(R2; Table 4), 69.59 percent of Atorvastatin, 48.29 of
Timolol and 76.47 percent of Latanoprost. If the variables
"publication year" or "treatment group" were entered an
additional 3.11–6.24 percent of the variability were
explained by the model. The variable "study size" added
not more than 0.23 percent.
If measuring the effect size in relative terms the results of
the multiple regression analysis were less homogenous,
but overall the year of publication was the most important
predictor for the reported effect size. For Pravastatin and
Timolol the variable "publication year" alone explained
28.73/19.58 percent of the effect size variability (R2; Table
4). For Pravastatin other variables did not add more than
0.68 percent when entered in the model, for Timolol
"baseline value" added 3.93 and "study size" 2.48 percent.
For the reported effect size of Atorvastatin, "treatment
group" was the most important predictor (R2 = .1882); of
Latanoprost, the "baseline value" (R2 = .5030).
Evaluation of potential bias
The funnel plot technique was used to evaluate Publica-
tion Bias. The study size was plotted against the reported
effect size of the study (Figure 3). The plots of Atorvastatin
and Latanoprost did not show relevant asymmetry, an
indication that significant Publication Bias was unlikely.
The plots of Pravastatin and Timolol showed slight asym-
metry. For example the Timolol studies including more
than 500 patients reported effect sizes of about 6 mmHg.
More of the smaller studies than represented on the fun-
nel plot should report effect sizes of less than 6 mmHg.
Discussion
The authors wish to stress that the investigated medical
interventions were chosen arbitrarily based on the criteria
stated in the methods section. We chose to conduct our
investigation using pharmaceutical interventions for
methodological reasons, but our theory is not limited to
drug therapies.
Reported effect size decreases over time
Our empirical evaluation of 206 randomised controlled
trials shows that the reported effect size of three of the
four investigated pharmaceuticals decreased significantly
over time. When Pravastatin, Timolol and Latanoprost
Table 4: Multiple regression analysis to explain the variability of the parameter "reported effect size". Shown are the top four models 
taking into account one or two variables with the effect size measured in absolute or in relative dimensions
Ranking of model Effect size measured in absolute terms Effect size measured in relative terms
Variables in model R2* Variables in model R2
Pravastatin 1 B, Y 0.8477 Y, B 0.2941
2 B, T 0.8077 Y, T 0.2916
3 B, n 0.8060 Y, n 0.2910
4 B 0.8037 Y 0.2873
Atorvastatin 1 B, T 0.7473 T, Y 0.2014
2 B, Y 0.6961 T, B 0.2001
3 B, n 0.6960 T, n 0.1957
4 B 0.6959 T 0.1882
Timolol 1 B, Y 0.5453 Y, B 0.2351
2 B, T 0.4948 Y, n 0.2206
3 B, n 0.4829 Y, T 0.1979
4 B 0.4829 Y 0.1958
Latanoprost 1 B, Y 0.7958 B, Y 0.5636
2 B, T 0.7798 B, T 0.5306
3 B, n 0.7649 B, n 0.5030
4 B 0.7647 B 0.5030
Abbreviations: Y, year of publication; B, baseline of parameter of interest; T, treatment group; n, study size.
* R2: Determination coefficient.BMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
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were new, studies reported them to be more effective than
studies that were conducted in later years. We refer to this
as "fading of reported effectiveness".
To many clinicians this phenomenon may induce the
impression that the "true" clinical improvement is not
that profound as suggested in medical publications. For
example in 1978, when the anti-glaucoma beta-blocker
Timolol was new, it was reported to lower the intraocular
pressure (IOP) by an average of 8.17 mmHg (calculated
from Figure 2). By1995, this figure decreased to an average
of 6.25 mmHg. More recently, the prostaglandin-analo-
gon Latanoprost was introduced in glaucoma therapy. In
1995, Latanoprost was reported to lower the IOP by an
average of 8.25 mmHg. Compared to Timolol in the same
year, Latanoprost was 2.00 mmHg more effective; com-
pared to Timolol in 1978, Latanoprost was equally effec-
tive. Improvement may have been more a matter of
perception than reality.
For one of the investigated pharmaceuticals there was no
significant change of the reported effectiveness over time.
For Atorvastatin analyses in relation to time may not yet
be feasible as the pharmaceutical is relatively new, and
there is very little variability of the publication date
(1999.40 ± 1.82; Table 1).
When conducting different trials about the same topic,
perfect consistency of the results certainly cannot be
expected. Even the best designed studies may differ in sev-
eral parameters, leading to a broad continuum of reported
effect sizes as shown in Figure 2. Schmid et. al. [30] dem-
onstrated previously that the observed treatment effect
generally depends from the baseline (or control) value.
This finding is expected, but a temporal trend in the devel-
opment of the continuum as described above must be the
result of other factors.
We are aware of methodological problems due to spuri-
ous regression when baseline values are correlated with
effect size. This however does not affect the qualitative
statements with respect to the correlation of baseline and
effect size [29].
Funnel plots; shown is the relation between study size and reported effectiveness Figure 3
Funnel plots; shown is the relation between study size and reported effectiveness. None of the relations are statistically signifi-
cant (Pravastatin P = 0.1327; Atorvastatin P = 0.8281; Timolol P = 0.2432; Latanoprost: P = 0.2251). Abbreviations: n, number 
of trials; IOP, intraocular pressure; LDL-C, low-density lipoprotein cholesterol.
	





  
  
  
  

	  







































                 ! "
#

$

%








$
&
'








(






"
	


 

 

 
  
 
  




































                 !"
#

$

%








$
&
'








(






"
	



 
 
	 


 








	









           ) *+   &&,"
#

$

%








$
&








(






"
	



 
 
	 


 








	









           ) *+   &&,"
#

$

%








$
&
'








(






"BMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
Page 10 of 12
(page number not for citation purposes)
Reasons for the decline of reported effectiveness
We investigated whether the decrease of the reported
effectiveness was influenced by the patients' baseline level
of disease, by the treatment assignment to experimental or
control group or by the study size.
Spectrum bias (a particular form of selection bias)
For all of the investigated medical therapies we studied,
the baseline values of the parameter of interest decreased
over time, i. e., patients who had been included in the ear-
lier trials were sicker than patients in later trials. This rela-
tion was highly significant for Pravastatin and Timolol
and just short of the chosen level of significance for Latan-
oprost (Table 2 and 3). The baseline values were, again,
the most important predictors of the reported effect size.
Our multiple regression analysis showed that up to 80.37
percent of the effect size variability was explained by the
baseline value differences (Table 4). We conclude that
most of the decline of reported effectiveness over time was
explained by the baseline value differences.
Decreasing publication bias
We found only weak evidence for the hypothesis that the
decline of reported effectiveness could be mediated by
study size. In theory, the combination of Publication Bias
and increased study size could contribute to the gradual
decrease in reported effect size. We found an increase in
study size over time for Timolol (P < .0001; Table 3) and
Pravastatin (P = .0517, not significant). The relation
between study size and reported effect size was weak. It
was significant only for Pravastatin and, then, only when
the outcome variable was measured in absolute terms (P
= .0139). We conclude that very little of the decrease of
reported effectiveness was influenced by the study size.
"Shift of treatment group" bias
We did not find evidence for the hypothesis that the treat-
ment assignment to experimental or control group influ-
enced its reported effect size, even though there was a
strong correlation between publication year and treat-
ment group (Table 3). The latter correlation was to be
expected since a medical therapy would be typically stud-
ied as the experimental therapy when new, and as the con-
trol therapy when established. The relation between
treatment group and effect size was very weak. The corre-
lation was significant only for Atorvastatin and only if the
treatment effect was measured in relative terms, surpris-
ingly favouring the control group. Nevertheless, the treat-
ment group is involved in several of the best multiple
regression analysis models (Table 4). These results must
be interpreted with care because of the problem of multi-
colinearity, especially between publication year and treat-
ment group.
Potential other influencing factors
Our study was limited in that we did not explore if param-
eters other than baseline value, treatment group and study
size contribute to the decrease of the reported effect size
over time. From the statistical view, there must be other
factors that play a role in the temporal development of the
reported effect size.
The influence of time of publication bias, study quality,
and financial conflicts of interest on study outcome are
known, but, to the best of our knowledge, it has not yet
been studied how temporal trends of these factors influ-
ence the reported effectiveness of medical therapies over
time.
The "time of publication bias", that has been described in
recent years, leads to an apparently decreasing effect size.
Several reports indicate that studies with positive or signif-
icant results are published on average two to three years
more rapidly than studies with negative or non-significant
results [10-12]. During the first years of a new pharmaceu-
tical being available, while the publication of studies with
negative results is delayed, studies with positive outcomes
will dominate in meta-analyses; the size of the treatment
effect may thus be overestimated. Little by little, the aver-
age reported effect size will decrease to a lower level when
studies with negative results are also published. In future
meta-analyses, this bias could be addressed by taking into
account the date of study completion and not the date of
publication.
Changes in study quality may be related to the decrease in
reported effect size. During the last decades methodologi-
cal trial quality has improved significantly in many areas
of medicine [13,14]. There are a substantial number of
reports that higher study quality is associated with lower
estimates of treatment effects [15-19]. This may contrib-
ute to our observation that the reported effectiveness of
medical therapies fades over time. In our meta-analysis we
did not assess study quality because of the well-known
lack of established quality scores [20,21], and because it is
often impossible to distinguish study quality from report-
ing quality. Nevertheless, future meta-analyses should
take into consideration the effect of trial quality develop-
ment.
Unlike the other described factors, the problem of finan-
cial conflicts of interest on the part of scientists is likely to
lead to an increase in reported effectiveness over time. In
our meta-analysis this effect may have mitigated the size
of the observed decrease in reported effect size. In the
United States, industry's share of total investment in bio-
medical research and development grew from approxi-
mately 32 percent in 1980 to 62 percent in 2000 [22], and
more and more industry sponsorship is being reported inBMC Medical Research Methodology 2006, 6:25 http://www.biomedcentral.com/1471-2288/6/25
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many areas of medicine [13,23,24]. It is well known in the
literature that studies funded by for-profit-organizations
are more likely to recommend the experimental therapy as
treatment of choice and less likely to report unfavourable
conclusions [22,25-27]. So the reported effectiveness
could improve with time. We did not investigate the role
of competing financial interests in our meta-analysis
because we could not determine which authors adhered
to the disclosure guidelines [24,28], but further studies
should address this issue.
Consequences for the validity of meta-analyses
This study suggests that the effectiveness of medical thera-
pies, as reported in RCTs, is not necessarily constant but
that it may decline with time. A meta-analysis sums up
evidence from a high number of RCTs that are conducted
usually over an extensive period of time. If fading of
reported effectiveness is present, the result of a meta-anal-
ysis depends on when it was performed:
(1) A meta-analysis investigating the effectiveness of one
single medical therapy that was conducted when the ther-
apy was relatively new may estimate higher treatment
effects than a meta-analysis that was conducted later.
(2) A meta-analysis comparing the effectiveness of two or
more different medical therapies may come to distorted
results favouring the newer therapies.
We conclude that the validity of a meta-analysis where the
described phenomenon is present may be impaired. In
order to establish a maximum of transparency, we pro-
pose to include a test for this phenomenon in future meta-
analyses. In our view it would be sufficient to plot effect
size against publication year, as shown in Figure 2, and to
calculate the significance level and the equation of the
regression line of this correlation. Given this information,
the reader could make up his own mind if the validity of
the meta-analysis may be undermined.
Conclusion
In conclusion, the current meta-analysis suggests that the
effectiveness of medical therapies, as reported in ran-
domised controlled trials, may decrease over time. We call
this phenomenon "fading of reported effectiveness". Base-
line differences could be identified as the main factor con-
tributing to this effect; changes in study size or treatment
group did not play a significant role. As the validity of a
meta-analysis where the fading of reported effectiveness is
present may be undermined, we propose to consider this
problem in future meta-analyses.
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